FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2595367007> ?p ?o ?g. }

• W2595367007 abstract "Abstract 4967 Introduction Myelofibrosis (MF) is a clonal stem cell Philadelphia chromosome negative myeloproliferative neoplasm (MPN) characterized by progressive cytopenias, massive splenomegaly, early satiety, and a hypercatabolic state manifested by fevers, fatigue, and weight loss. Approximately 10-20% of MF patients will transform to acute myeloid leukemia (AML) over a 10-year period with a median overall survival at time of transformation of 2.6 months (Mesa 2005). In a multivariate analysis, peripheral blood blast count > 3% and/or a platelet count < 100 × 109/L at time of diagnosis of MF were independent risk factors for leukemic transformation (LT) (Huang 2008). Standard induction chemotherapy improved survival to 3.9-5 months (Mesa 2005, Tam 2008). Survival was decreased due to a high relapse rate and treatment-related mortality. Patients who received an allogeneic stem cell transplant early in the disease course had superior survival. We describe the outcome of ten consecutive patients with MF-LT at our institution. Patients and Methods A retrospective chart review was performed to evaluate patients with MF-LT, including clinical characteristics, therapies administered, and survival outcomes. Between the years of 2007 and 2009, ten MF-LT patients were identified in our institution. The median age was 66 (range 45-77) with 60 percent male and 40 percent female patients. Thirty percent (3/10) of patients were JAK2 V617F positive. Seven patients were cytogenetically abnormal and three had a normal karyotype. Chromosomal abnormalities included +1q (2 pts), +8 (2 pts), -7 (2 pts), inv 3 (1 pt), and t(6;9) (1 pt). Fifty percent of patients had a post-essential thrombocythemia related MF, while 30 percent had an MDS/MF overlap syndrome. Time to LT ranged from 3 months to 12 years with a median of 12 months. In three cases, there was discordance between bone marrow blasts by immunohistochemical staining and peripheral blood manual count. Six patients were treated with decitabine at 20 mg/m2 for 5 days (for two to ten cycles), and four received reduced intensity conditioning allogeneic stem cell transplantation (RIC-ASCT). Patients were eligible for RIC-ASCT if they were under 70 years of age, had no significant comorbidities, and had either an HLA compatible sibling or an unrelated donor with at most one mismatched allele. Results The median survival from diagnosis of LT with the use of decitabine has not yet been reached but exceeds 7.5 months in this patient population. Two out of six patients treated with decitabine died 6 and 8 months after LT. The remaining four patients are still alive at 6, 7, 9, and 36 months after LT and are actively receiving therapy. Four out of six patients who received decitabine had subjective improvement in fatigue as well as decrease in splenomegaly. Three out of six patients had a decrease in transfusion requirements. The four patients who underwent RIC-ASCT are all alive after a median follow-up of 16.5 months with no evidence of leukemia in the bone marrow. Conclusions These results demonstrate that single-agent decitabine for those who are not eligible for transplant or RIC-ASCT for eligible patients, leads to a significant improvement in overall survival. Further investigation using these therapeutic modalities is warranted given the aggressive nature of this disease. Furthermore, the noted discordance between bone marrow and peripheral blood blast percentage most likely reflects leukemic cell production originating at sites of extramedullary hematopoiesis. Disclosures No relevant conflicts of interest to declare." @default.
• W2595367007 created "2017-03-23" @default.
• W2595367007 creator A5006372952 @default.
• W2595367007 creator A5042829932 @default.
• W2595367007 creator A5054251988 @default.
• W2595367007 creator A5072336042 @default.
• W2595367007 date "2009-11-20" @default.
• W2595367007 modified "2023-09-30" @default.
• W2595367007 title "Effective Management of Patients with Leukemic Transformation of Myelofibrosis." @default.
• W2595367007 doi "https://doi.org/10.1182/blood.v114.22.4967.4967" @default.
• W2595367007 hasPublicationYear "2009" @default.
• W2595367007 type Work @default.
• W2595367007 sameAs 2595367007 @default.
• W2595367007 citedByCount "0" @default.
• W2595367007 crossrefType "journal-article" @default.
• W2595367007 hasAuthorship W2595367007A5006372952 @default.
• W2595367007 hasAuthorship W2595367007A5042829932 @default.
• W2595367007 hasAuthorship W2595367007A5054251988 @default.
• W2595367007 hasAuthorship W2595367007A5072336042 @default.
• W2595367007 hasConcept C126322002 @default.
• W2595367007 hasConcept C141071460 @default.
• W2595367007 hasConcept C2776694085 @default.
• W2595367007 hasConcept C2778336483 @default.
• W2595367007 hasConcept C2779282312 @default.
• W2595367007 hasConcept C2780007613 @default.
• W2595367007 hasConcept C2780076729 @default.
• W2595367007 hasConcept C2781107747 @default.
• W2595367007 hasConcept C71924100 @default.
• W2595367007 hasConcept C90924648 @default.
• W2595367007 hasConceptScore W2595367007C126322002 @default.
• W2595367007 hasConceptScore W2595367007C141071460 @default.
• W2595367007 hasConceptScore W2595367007C2776694085 @default.
• W2595367007 hasConceptScore W2595367007C2778336483 @default.
• W2595367007 hasConceptScore W2595367007C2779282312 @default.
• W2595367007 hasConceptScore W2595367007C2780007613 @default.
• W2595367007 hasConceptScore W2595367007C2780076729 @default.
• W2595367007 hasConceptScore W2595367007C2781107747 @default.
• W2595367007 hasConceptScore W2595367007C71924100 @default.
• W2595367007 hasConceptScore W2595367007C90924648 @default.
• W2595367007 hasLocation W25953670071 @default.
• W2595367007 hasOpenAccess W2595367007 @default.
• W2595367007 hasPrimaryLocation W25953670071 @default.
• W2595367007 hasRelatedWork W154474755 @default.
• W2595367007 hasRelatedWork W2405127024 @default.
• W2595367007 hasRelatedWork W2505156634 @default.
• W2595367007 hasRelatedWork W2531810619 @default.
• W2595367007 hasRelatedWork W2555678589 @default.
• W2595367007 hasRelatedWork W2556333970 @default.
• W2595367007 hasRelatedWork W2567594949 @default.
• W2595367007 hasRelatedWork W2568989399 @default.
• W2595367007 hasRelatedWork W2575449152 @default.
• W2595367007 hasRelatedWork W2585032392 @default.
• W2595367007 hasRelatedWork W2587351747 @default.
• W2595367007 hasRelatedWork W2588142421 @default.
• W2595367007 hasRelatedWork W2588583062 @default.
• W2595367007 hasRelatedWork W2591763181 @default.
• W2595367007 hasRelatedWork W2594871545 @default.
• W2595367007 hasRelatedWork W2605415016 @default.
• W2595367007 hasRelatedWork W2979730270 @default.
• W2595367007 hasRelatedWork W2979796411 @default.
• W2595367007 hasRelatedWork W2980007933 @default.
• W2595367007 hasRelatedWork W2993862984 @default.
• W2595367007 isParatext "false" @default.
• W2595367007 isRetracted "false" @default.
• W2595367007 magId "2595367007" @default.
• W2595367007 workType "article" @default.